 This trial is aimed at studying the safety of long term supervised treatment interruption in HIV infected patients with CD4 over 350mm3 and plasma HIV RNA under 50 000mL. Another aim of this study is to assess the immunological and virological factors associated with the duration of treatment interruption. 